Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
← Psychiatry indexChapter sections
OverviewAetiologyPathophysiologyClinical features and red flagsInvestigationsDifferential diagnosisManagementComplicationsMonitoring and follow-upSpecial situationsCommon pitfallsQuestionsSources
Full textbook13 sectionsOpen only what you need
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.

Extrapyramidal symptoms and tardive dyskinesia

Psychiatry · UK scope · Sources checked 7 Sept 2026 · Clinical review pending

RapidFull
!
Dystonia can threaten the airway

Acute tongue, jaw, pharyngeal or laryngeal contraction after a dopamine-blocking medicine may impair breathing or swallowing and can be mistaken for panic or an allergic reaction.

Action: Call for emergency airway support, stop the suspected precipitant and give an appropriate parenteral anticholinergic promptly through the acute-care protocol while monitoring response and ventilation.

Overview

Distinguish acute dystonia, parkinsonism, akathisia and tardive dyskinesia by their timing and movement pattern, then select treatment that relieves the actual syndrome without worsening another motor adverse effect.

Extrapyramidal symptoms are a group of syndromes, not a single diagnosis with one treatment. Begin by asking what the movement feels like, observing its form and establishing its relation to medicine exposure. Include antiemetics such as metoclopramide and prochlorperazine, not only antipsychotics. Record recent injections, dose increases, reduced doses and anticholinergic withdrawal. Several syndromes can coexist, making a reflex prescription of procyclidine particularly unhelpful.

Dystonia consists of sustained muscle contraction, often affecting the neck, eyes, jaw or tongue. It may occur after a single dose and can be frightening despite preserved awareness. A patient with an oculogyric crisis may appear behaviourally disturbed while being unable to control the eye position. Rapid recognition avoids repeated dopamine-blocking sedation and allows effective rescue treatment. Airway involvement is an emergency even if other observations initially appear reassuring.

Parkinsonism is characterised by bradykinesia with rigidity or tremor. It is often relatively symmetrical after medication exposure, but asymmetry does not exclude a drug contribution. A dopamine blocker may also reveal pre-existing Parkinson's disease. Review gait, handwriting, swallowing and daily activities, and refer persistent or diagnostically uncertain cases for neurological assessment. Sedation and negative symptoms can look like slowed movement but

Aetiology

01

Dopamine-receptor blocking medicines

Antipsychotics and several antiemetics can disturb motor signalling, with risk influenced by potency, dose, route, rapid escalation and individual susceptibility.

02

Duration and susceptibility

Prior movement reactions, age, cumulative exposure and neurological vulnerability influence risk; tardive syndromes usually follow longer exposure but are not confined to one drug class.

Pathophysiology

  1. 1
    Nigrostriatal dopamine reduction

    Reduced dopaminergic transmission alters basal ganglia motor output, producing slowed movement, rigidity and an imbalance that can favour sustained dystonic contraction.

  2. 2
    Motor and subjective restlessness

    Akathisia involves disturbed motor and arousal regulation, producing both an experienced compulsion to move and observable activity that temporarily relieves discomfort.

  3. 3
    Chronic motor adaptation

    Long-standing dopamine blockade can induce persistent changes in receptor sensitivity and motor circuits, contributing to dyskinetic movements that may outlast drug withdrawal.

Clinical features and red flags

Acute dystonic posture

Torticollis, jaw spasm, protruding tongue or sustained upward eye deviation appears shortly after a dopamine blocker, sometimes with preserved but distressed communication.

Parkinsonian examination

Look for reduced spontaneous movement, cogwheel or lead-pipe rigidity, tremor and reduced arm swing, then assess falls and swallowing.

Subjective akathisia

Pacing and shifting weight are accompanied by an inner compulsion to move, often temporally linked to treatment initiation or escalation.

Tardive pattern

Lip smacking, chewing, tongue movements, finger movements or truncal rocking follow chronic exposure and may persist despite withdrawal.

Red flags requiring action

  • Stridor, dysphagia, cyanosis or inability to handle secretions during a suspected dystonic reaction requires immediate resuscitation assessment.
  • Fever, generalised severe rigidity, confusion and unstable observations suggest neuroleptic malignant syndrome rather than uncomplicated parkinsonism.
  • Severe akathisia can produce intolerable distress and suicidal thinking; assess immediate safety as well as the movement disorder.

Investigations

  1. 01
    Full exposure timelineFirst step
    Why
    Identify dopamine-blocking and anticholinergic changes that explain the movement.
    Interpretation and limitations
    A recent antiemetic can be the cause in someone with no psychiatric history; a long-acting injection may sustain symptoms after administration stops.
  2. 02
    Structured movement assessment
    Why
    Document phenotype, severity and the person's functional burden.
    Interpretation and limitations
    Use tools such as AIMS for dyskinesia or a Barnes scale for akathisia alongside examination; the score does not establish causation by itself.
  3. 03
    Targeted acute bloods and observations
    Why
    Identify systemic toxicity or metabolic mimics when clinically indicated.
    Interpretation and limitations
    Temperature, CK, renal function and electrolytes help assess a rigid febrile patient; uncomplicated isolated dystonia is usually a clinical diagnosis.
  4. 04
    Neurological evaluation for atypical or persistent findings
    Why
    Investigate alternative movement disorders when chronology or recovery is unconvincing.
    Interpretation and limitations
    Progressive asymmetrical signs, focal deficits or an atypical history may require specialist assessment and selected imaging rather than repeated empirical anticholinergic escalation.

Differential diagnosis

01

Parkinson's disease

Progressive parkinsonism may predate or be unmasked by treatment; asymmetry, non-motor history and persistence after a considered drug change justify neurological assessment.

02

Anxiety or restless legs

Anxiety may cause pacing without the characteristic inner motor urge, while restless legs is predominantly leg discomfort with a circadian and rest-related pattern.

03

Other dyskinetic disorders

Dental problems, spontaneous orofacial movements, Huntington's disease, tics and functional movement disorders can resemble a tardive syndrome and require contextual examination.

Management

01Acute rescueTreat a dystonic reaction promptlyFirst stepPainful sustained posturing or eye deviation develops after a relevant medicine.+
  1. 1Assess airway and swallowing, summon urgent support for respiratory involvement and stop the precipitating medicine.
  2. 2Administer the locally stocked parenteral anticholinergic using its own dosing instructions; benztropine is not milligram-equivalent to procyclidine.
  3. 3Reassess response, observe for recurrence and agree short-term follow-up treatment and avoidance of the precipitant before discharge.
02Restlessness or slowingMatch treatment to the phenotypeAkathisia or parkinsonian symptoms cause distress or functional difficulty during antipsychotic treatment.+
  1. 1AlternativeReview the antipsychotic dose, recent changes and whether a lower-risk alternative can preserve psychiatric control.

Complications

01

Airway compromise

Laryngeal or pharyngeal dystonia can obstruct breathing or impair swallowing, creating immediate respiratory danger and aspiration risk despite otherwise preserved consciousness.

02

Psychiatric disengagement

Distressing restlessness or visible movements can undermine trust and adherence, with unsupervised cessation increasing the risk of psychotic or mood relapse.

03

Persistent disability

Orofacial and limb dyskinesia can interfere with eating, speech, mobility and work, while stigma and loss of confidence further restrict participation.

Monitoring and follow-up

  • After dystonia rescue recheck airway, pain, swallowing, observations and recurrence, accounting for the duration of the precipitating drug.
  • Repeat the same structured movement assessment after medication changes and ask about function, social embarrassment and subjective distress.
  • Review anticholinergic burden and constipation at each relevant follow-up, especially in older people or those receiving clozapine.
  • When treating akathisia with propranolol under specialist advice, monitor pulse and blood pressure and avoid use in asthma or relevant conduction disease.
  • During tetrabenazine titration assess mood, suicidal thinking, sedation, parkinsonism and swallowing; new symptoms may require stopping escalation or reducing the dose.

Special situations

Movement after dose reduction

Tardive movements can be unmasked by reduced dopamine blockade; this does not automatically mean the person needs the former antipsychotic dose restored.

Akathisia and apparent non-adherence

Skipping medication may be an attempt to escape unbearable restlessness, so treating the adverse effect can restore engagement more effectively than warnings alone.

Different imported product

Benztropine ampoules and dosing differ from former procyclidine stock, requiring explicit prescribing, administration instructions and applicable Mental Health Act treatment-form coverage.

Cognitive cost of treatment

An anticholinergic may reduce rigidity yet impair memory or cause urinary retention, so motor improvement is not the sole measure of success.

Common pitfalls

  1. 01

    Giving another dopamine-blocking antiemetic or sedative to a patient whose acute dystonia has been mistaken for behavioural agitation.

  2. 02

    Using procyclidine to treat every involuntary movement, including tardive dyskinesia that it may worsen.

  3. 03

    Missing subjective akathisia because the patient briefly suppresses pacing during the consultation.

  4. 04

    Assuming all generic tetrabenazine products have identical licensed indications without checking the selected SmPC.

  5. 05

    Discharging after a rapid response without discussing recurrence, the culprit medicine and the follow-up plan.

Practice

Two practice questions

Your practice draft is saved in this browser.

Question 1 of 2
0 correct
PsychiatryOriginal SBA

Treatment depends on phenotype

A patient on long-term haloperidol develops repetitive tongue and lip movements. There is no rigidity or subjective restlessness. They already take procyclidine. Which management principle is most appropriate?

Choose one answer, then submit
← Rapid synopsisBack to overviewAll Psychiatry topics →
Sources and review status4 sources · checked 7 Sept 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 7 Sept 2026; clinical approval remains outstanding.

  • NHS GGC extrapyramidal side-effect managementPhenotypes and syndrome-specific management.
  • SPS benztropine injection August 2026Procyclidine discontinuation, imported benztropine and doses.
  • Procyclidine 5 mg tablets SmPCOral drug-induced parkinsonism dosing and cautions.
  • Tetrabenazine 25 mg Zydus SmPCLicensed tardive indication, initial dose and contraindications.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom
do not
reproduce the same motor examination.

Akathisia is particularly easy to misinterpret. Ask whether sitting still is physically unbearable, whether walking brings brief relief, and whether the sensation began after a dose change. Anxiety, agitation, restless legs and substance withdrawal remain alternatives. Tardive dyskinesia, in contrast, involves involuntary repetitive movements that may be initially subtle and sometimes become more visible after antipsychotic reduction. Assess chewing, speech, swallowing, embarrassment and occupational impact, not just movement amplitude.

Management balances motor harm against the original psychiatric indication. Reduce unnecessary exposure where possible, consider a lower-risk antipsychotic with the specialist team and avoid indefinite medicines added simply to counter another prescription. Persistent disabling tardive dyskinesia may warrant specialist monoamine-depleting treatment or a clozapine discussion in an appropriate psychiatric context. The diagnosis, likely reversibility and uncertainty should be explained carefully; disappearance after one dose adjustment cannot be promised.

Key points

  • Acute dystonia usually follows recent exposure or dose escalation and causes sustained, often painful abnormal postures or an oculogyric crisis.
  • Drug-induced parkinsonism produces slowed movement, rigidity and tremor; review dopamine blockers before labelling a new degenerative disorder.
  • Akathisia combines an internal urge to move with observable restlessness and usually responds poorly to anticholinergics.
  • Tardive dyskinesia commonly causes repetitive tongue, lip, facial, limb or truncal movements after longer dopamine-blocker exposure.
  • Anticholinergics can help acute dystonia or parkinsonism but may aggravate tardive dyskinesia and should not be routine prophylaxis.
  • UK procyclidine injection has been discontinued; the 2026 SPS guidance describes imported, UK-unlicensed benztropine injection for acute dystonia.
  • Changes to the causative antipsychotic need a psychiatric relapse plan, especially when movements emerge during dose reduction.
2
Consider a time-limited anticholinergic for parkinsonism, while recognising it is usually ineffective for isolated akathisia.
  • 3For akathisia discuss specialist options such as propranolol or a short benzodiazepine course, documenting off-label use and relevant cardiovascular, respiratory and dependence risks.
    • 03Persistent dyskinesiaPlan specialist tardive managementRepetitive involuntary movements persist after long-term dopamine-blocker exposure.+
    1. 1Document baseline movements and functional impact, and examine for competing neurological or dental explanations.
    2. 2Review anticholinergics and minimise unnecessary dopamine blockade through a gradual psychiatric plan rather than an abrupt unsupervised stop.
    3. 3Refer disabling persistent symptoms for specialist treatment assessment, including product-specific licensed tetrabenazine where suitable and review of depression or suicide risk.
    Key medicines and prescribing safety3 treatments · regimens, roles and cautions+
    A rapid anticholinergic rescue option described by SPS after UK procyclidine injection discontinuation.

    Benztropine injection for adult acute dystonia

    Give 1–2 mg intramuscularly or intravenously; if there is no response a repeat may be given after 30 minutes intramuscularly or 10 minutes intravenously, within the authorised daily maximum.

    UK use is unlicensed; SPS reports daily maxima of 4–6 mg and gives a 4 mg/24-hour example. Specify route and maximum explicitly, consider cumulative anticholinergic exposure and do not assume dose equivalence.

    A symptomatic option for troublesome drug-induced parkinsonism while causative antipsychotic treatment is reviewed.

    Oral procyclidine for drug-induced parkinsonism

    Start 2.5 mg orally three times daily, then adjust cautiously to response; the cited tablet SmPC usually uses 10–20 mg daily in divided doses.

    Avoid routine prophylaxis and review continuing need; constipation, urinary retention, glaucoma risk, confusion and worsening tardive dyskinesia may outweigh benefit.

    A product-specific option when appropriate antipsychotic reduction, withdrawal or switching has not resolved disabling symptoms or is unrealistic.

    Tetrabenazine for persistent disabling tardive dyskinesia

    The cited licensed product starts at 12.5 mg orally daily, followed by specialist titration to response; discontinue if there is no clear benefit or adverse effects are intolerable.

    Contraindicated with active suicidality, poorly controlled depression, hepatic impairment, parkinsonism or MAO inhibitors; monitor mood, sedation, QT risk and CYP2D6 interactions.